Last week, the New York Times posted an online poll asking its readers to choose which three of 15 possible questions they'd like to see the candidates address during the debates, which kick off Monday night. Only one touched on healthcare.
Medicare's new payment system for physicians is causing anxiety because of the short stretch of road before their performance is judged for a raise or pay cut. In the long-term, though, Medicare and most everyone else want providers to leave that new system behind. It's value-based training wheels.
A key part of Modern Healthcare's mission is to help providers, payers and suppliers—our readers—with the news, information and data to succeed on higher-quality, lower-cost and more patient-centric care. That's why we are launching the Transformation Hub on our website.
No one has articulated a strategy for removing the estimated 350,000 mentally ill people incarcerated in the nation's jails and prisons. And no one is talking about how to fund a sharp increase in the number of long-term psychiatric beds in hospitals and other institutions. They clearly are needed.
There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.
Michelle Obama during her nearly eight years in the White House succeeded in changing the national conversation about diet and exercise, and gave a major boost to transparency about the foods we eat.
The harsh reality of modern-day America is that the less-educated, hourly workforce is falling further and further behind those still clinging to middle class status and above. This is a fairness issue that today characterizes almost every sector of the U.S. economy—including healthcare.
Don't hold your breath waiting for members of Congress to return to Washington to deal with the immediate public health threat posed by the Zika virus. That would require putting the public interest over politics, an approach gone missing in action during this poisonous election year.
Rulemakers in outgoing administrations usually end their tenures with a bang, not a whimper. President Barack Obama's appointees at the CMS are no exception.
A superficial reading of the latest headlines about the health insurance industry suggests it is facing serious problems, but the steady drumbeat of bad news for insurers is showing up everywhere except in the finances of the major carriers.
Last week, two well-respected groups of government economists predicted the end is nigh for the era of restrained growth in healthcare spending. Ignore them. They've been wrong before. They will be proven wrong again.
Medicare's first step in reining in the skyrocketing cost of specialty drugs deserves support—something it has not received from hospitals, doctors, politicians or, of course, the pharmaceutical industry, which benefits the most from the status quo.